Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer

Condition:   Ovarian Cancer Intervention:   Drug: Anlotinib Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials